

# DRL unveils Vasostrict generic in U.S.

SPECIAL CORRESPONDENT

HYDERABAD

Dr. Reddy's Laboratories (DRL) on Wednesday unveiled its authorised generic version of Par Pharmaceutical's Vasostrict (vasopressin injection, USP) vials in the U.S.

The Vasostrict brand market had U.S. sales of about \$878.5 million for the most recent twelve months ended December, the company said, citing IQVIA Health numbers.

Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock. DRL's Vasopressin Injection, USP, comes in a carton of 25 single-dose vials each containing vasopressin 1 mL at 20 units/mL, it said in a release.